posted on 06 Jun 2019
Nuvaira deploys a ground-breaking therapy called targeted lung denervation. It’s based on the discovery that a faulty nerve that runs from the brain to the lungs may be partly to blame for asthma flare-ups.
For many years, the illness was thought to be due solely to the immune system overreacting to allergens – such as pollen – or viruses, like a cold. But scientists now know it can also be worsened by problems with the vagus nerve – a twisting bundle of pathways running from the chest to the brain.
Branches of the vagus nerve control the muscles in the airways that manage the breathing. In healthy lungs, the nerve sends signals to the muscles to ensure they contract and relax smoothly, allowing the airways to inhale and exhale properly.
But if the nerves are faulty, these muscles become overactive. As they tighten more and relax less, the airways become narrowed and breathing becomes harder. Destroying these branches of the vagus nerve blocks the faulty signals, stopping the muscles in the airways from tightening and allowing more air to pass into the lungs.
Denervation involves the patient being given a general anaesthetic and a device called a bronchoscope being inserted through the mouth and into the lungs.
[Nuvaira] has already proved successful in treating patients who suffer from chronic obstructive pulmonary disorder – a severe breathing problem often, but not always, caused by smoking.
Now 30 asthma patients at hospitals in the UK, France, Germany, and the Netherlands, including some treated on the NHS, will receive the therapy as part of a three-year clinical trial.
For more details, please see the article on DailyMail UK here
PerimeterX, the leading provider of application security solutions that keep web businesses safe in the complex digital world, today announced that it has been named the winner of the “Overall CyberSecurity Startup of the Year” award in the 2019 CyberSecurity Breakthrough Awards program from CyberSecurity Breakthrough, a leading independent market intelligence organization that recognizes the top companies, technologies and products in the global information security market today.
Vertex Growth Fund achieves a resounding final close of its inaugural fund – Vertex Growth Fund I – at USD290 million. Demand for the fund surpassed the initial target fund size of USD250 million.
Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diabetic eye disease, today reports positive topline data from a Phase 1 study with THR-149, a novel, potent, plasma kallikrein (PKal) inhibitor for the treatment of Diabetic Macular Edema (DME).